NCT01588145View on ClinicalTrials.gov

Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

273

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

HM61713

BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops

Trial Locations (1)

Unknown

Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT01588145 - Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients | Biotech Hunter | Biotech Hunter